0001193125-26-116164
SEC filingEledon Pharmaceuticals, Inc. (ELDN), a clinical-stage immunology-focused biopharmaceutical company, reported a FY 2025 net loss of $45.6 million, widened from $36.2 million in 2024, driven by total operating expenses of $83.3 million including $66.3 million research and development and $17.0 million general and administrative. Other net income of $4.2 million was outweighed by a $33.4 million unfavorable change in fair value of warrant liabilities, yielding pretax and net loss of $45.6 million after $35K tax provision. Basic and diluted EPS were -$1 with 81.8 million weighted shares. Cash burn from operations escalated to $62.3 million from $47.3 million YoY, attributable to higher net loss, stock-based compensation of $10.5 million, and working capital shifts amid kidney transplantation programs. Financing inflows totaled $53.8 million, led by $53.6 million net from the 2025 Underwritten Offering of 19.7 million common shares and 15.2 million pre-funded warrants, plus $0.2 million option exercises. Investing netted $10.8 million positive from $171.9 million short-term investment maturities exceeding $161.1 million purchases. Net cash change +$2.3 million. Balance sheet reflects total assets $169.0 million with current assets $135.7 million (cash and equivalents $22.8 million, short-term investments $110.5 million). Liabilities $32.2 million including warrant liabilities $11.4 million; convertible preferred stock $55.7 million; stockholders' equity $81.1 million. Investor significance: Solid liquidity supports pipeline advancement, but heightened burn signals need for further capital amid raising challenges and $0.7 million lease payments through 2027.
Eledon Pharmaceuticals, Inc. reported a net loss of $45.6 million for the year ended December 31, 2025, compared to a $36.2 million net loss in 2024, reflecting a 26% increase in loss magnitude. Total operating expenses rose to $83.3 million from implied lower prior-year levels, consisting of $66.3 million in research and development expenses and $17.0 million in general and administrative expenses. Other income, net, contributed $4.2 million positively. However, a $33.4 million change (expense) in fair value of warrant liabilities drove the loss before income taxes to $45.6 million, with a minimal $35K provision for income taxes. Comprehensive loss was also $45.6 million after a $2K unrealized loss on available-for-sale securities. Basic and diluted earnings per share were both -$1, based on 81.8 million weighted-average common shares outstanding. Shares issued and outstanding increased to 75,430,033 from 59,789,275. This performance underscores intensified R&D investment in kidney transplantation programs amid no revenue generation. (152 words)
No revenue was reported for FY 2025, consistent with Eledon Pharmaceuticals' status as a pre-commercial, clinical-stage biopharmaceutical company developing immunobiology therapeutics for kidney transplant rejection and other indications. Operating expenses serve as the primary activity metric, with no segment revenue breakdown, geographic mix, or product-specific drivers disclosed. Functional expenses highlight R&D dominance at $66.3 million (80% of total operating expenses), supporting preclinical and clinical studies, manufacturing, and third-party contracts. G&A at $17.0 million covered administrative functions. Prior-year expense details not segmented, but overall cash usage increase tied to expanded kidney transplantation efforts. No long-term manufacturing agreements; contracts with CROs and suppliers are terminable with notice. (118 words)
Absent revenue, traditional margins are not applicable. Implied operating loss (operating expenses $83.3 million less other income $4.2 million) totaled approximately $79.1 million before warrant adjustments. Net loss margin N/A. Profitability pressured by R&D-heavy cost structure (80% of op ex), with non-cash items including $10.5 million stock-based compensation and volatile $33.4 million warrant liability fair value change (negative vs. prior $30.9 million impact, likely favorable). Deferred tax provision $5K in cash flow reconciliation. Accumulated deficit grew to $401.2 million. Trends show escalating expenses without revenue offset, highlighting dependency on financing for sustainability. (102 words)
Net cash used in operating activities was $62.3 million in 2025, up $15.0 million from $47.3 million in 2024, driven by $45.6 million net loss, offset by non-cash items like $10.5 million stock comp and warrant fair value change adjustment, plus $6.7 million accounts payable/accrued increase. Investing provided net $10.8 million (proceeds from short-term investments $171.9 million exceeding purchases $161.1 million). Financing yielded $53.8 million, primarily $53.6 million from 2025 Underwritten Offering. Net change in cash and equivalents +$2.3 million.
Balance sheet: total assets $169.0 million (current $135.7 million: cash/equivalents $22.8 million, short-term investments $110.5 million, prepaids $2.4 million); in-process R&D $32.4 million. Liabilities $32.2 million (current $18.3 million, warrant liabilities $11.4 million). Convertible preferred stock $55.7 million; stockholders' equity $81.1 million (APIC $482.2 million, accum deficit -$401.2M). Strong current ratio supports ~18-24 months runway at current burn. (168 words)
Management notes substantial capital requirements to fund clinical development, preclinical studies, and operations, with challenges in raising additional capital emphasized in Risk Factors. Recent $53.8 million financing extends runway, but ongoing dilution from offerings, pre-funded warrants, and exercises noted. Lease obligations total $0.7 million through 2027 for Irvine, CA (expires June 2027) and Burlington, MA (November 2027) facilities. CRO and supply contracts terminable post-notice; no material non-cancelable beyond leases. Warrant liabilities remain at $11.4 million, subject to fair value volatility. Strategic priorities center on kidney transplantation programs, with no quantitative guidance provided. Forward-looking risks include funding needs and execution on trials. (124 words) (Total: 664 words)